Trials
1 active
2 in total
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
- Main trialPhase 2/3
- “This is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced or metastatic biliary tract cancers.”In the company’s words, NCT05506943 on ClinicalTrials.gov
Other drugs for Biliary Tract Cancer
- Trastuzumab deruxtecanDaiichi Sankyo · AstraZeneca · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- RilvegostomigAstraZeneca · Phase 3
- NanvuranlatJ-Pharma Co., Ltd. · Phase 3
- DurvalumabAstraZeneca · Phase 3
- ZanidatamabJazz Pharmaceuticals · Phase 3
Coming up1
- 31 Aug 2027Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Active, not recruiting | 31 Aug 2027 | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) | |
| Phase 2Completed | 15 May 2025 | A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026